Pfizer CEO On Moving Beyond COVID Vaccines To Lead In Cancer And Obesity Treatments
WASHINGTON (AP) — Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. Today, CEO Albert Bourla is trying to turn the page from that success story, which has turned into more of a financial headache for the global drugmaker. Lofty expectations for continuing sales of vaccines and antivirals have fallen short, sending Pfizer’s stock price tumbling to about half of its peak during the pandemic. Bourla has responded with a $4 billion cost-cutting effort, including layoffs, and ...